Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab vs FMT for Multiple Recurrent CDI
NCT05077085Phase 4Withdrawn
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of bezlotoxumab in Clostridioides difficile infection (CDI), sponsored by Leiden University Medical Center. Planned start Jan 2022; status: withdrawn.
02
Drugs
bezlotoxumab
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT05077085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077085.